+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Musculoskeletal Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5292712
  • Report
  • February 2021
  • Region: Global
  • 300 pages
  • The Business Research Company

FEATURED COMPANIES

  • Abbott Laboratories Inc
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd
  • GlaxosmithKline Plc
  • Pfizer Inc
Musculoskeletal Disorders Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global musculoskeletal disorders drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the musculoskeletal disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Musculoskeletal Disorders Drugs market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider musculoskeletal disorders drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The musculoskeletal disorders drugs market section of the report gives context. It compares the musculoskeletal disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, musculoskeletal disorders drugs indicators comparison.
Scope

Markets Covered:
1) By Type: Drugs For Rheumatoid Arthritis; Muscle Relaxants; Other Musculoskeletal Disorders Drugs
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: F. Hoffmann-La Roche Ltd; GlaxosmithKline Plc; Pfizer Inc; Abbott Laboratories Inc; Daiichi Sankyo Company

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, musculoskeletal disorders drugs indicators comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Inc
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd
  • GlaxosmithKline Plc
  • Pfizer Inc
1. Executive Summary

2. Report Structure

3. Musculoskeletal Disorders Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Musculoskeletal Disorders Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Musculoskeletal Disorders Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Musculoskeletal Disorders Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Musculoskeletal Disorders Drugs Market Trends and Strategies

8. Impact of COVID-19 on Musculoskeletal Disorders Drugs

9. Musculoskeletal Disorders Drugs Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market

10. Musculoskeletal Disorders Drugs Market Regional Analysis
10.1. Global Musculoskeletal Disorders Drugs Market, 2020, by Region, Value ($ Billion)
10.2. Global Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Musculoskeletal Disorders Drugs Market, Growth and Market Share Comparison, by Region

11. Musculoskeletal Disorders Drugs Market Segmentation
11.1. Global Musculoskeletal Disorders Drugs Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Drugs for Rheumatoid Arthritis
  • Muscle Relaxants
  • Other Musculoskeletal Disorders Drugs
11.2. Global Musculoskeletal Disorders Drugs Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Others
11.3. Global Musculoskeletal Disorders Drugs Market, Segmentation by Route of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Others
11.4. Global Musculoskeletal Disorders Drugs Market, Segmentation by Drug Classification, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Branded Drugs
  • Generic Drugs
11.5. Global Musculoskeletal Disorders Drugs Market, Segmentation by Mode of Purchase, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs
12. Musculoskeletal Disorders Drugs Market Metrics
12.1. Musculoskeletal Disorders Drugs Market Size, Percentage of GDP, 2015-2025, Global
12.2. Per Capita Average Musculoskeletal Disorders Drugs Market Expenditure, 2015-2025, Global

13. Asia-Pacific Musculoskeletal Disorders Drugs Market
13.1. Asia-Pacific Musculoskeletal Disorders Drugs Market Overview
  • Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
13.2. Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2020, by Country, Value ($ Billion)
13.3. Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
13.4. Asia-Pacific, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
13.5. Asia-Pacific, Musculoskeletal Disorders Drugs Market Metrics
13.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2015-2025, Asia-Pacific Countries
13.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2020, Asia-Pacific Countries
13.6. Asia-Pacific Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7. Asia-Pacific Musculoskeletal Disorders Drugs Market: Country Analysis
13.7.1. China Musculoskeletal Disorders Drugs Market
13.7.1.1. China Musculoskeletal Disorders Drugs Market Overview
13.7.1.2. China Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.1.3. China Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2. Australia Musculoskeletal Disorders Drugs Market
13.7.2.1. Australia Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.2.2. Australia Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.3. Hong Kong Musculoskeletal Disorders Drugs Market
13.7.3.1. Hong Kong Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4. India Musculoskeletal Disorders Drugs Market
13.7.4.1. India Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.4.2. India Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5. Indonesia Musculoskeletal Disorders Drugs Market
13.7.5.1. Indonesia Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.5.2. Indonesia Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6. Japan Musculoskeletal Disorders Drugs Market
13.7.6.1. Japan Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.6.2. Japan Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.7. Malaysia Musculoskeletal Disorders Drugs Market
13.7.7.1. Malaysia Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.8. New Zealand Musculoskeletal Disorders Drugs Market
13.7.8.1. New Zealand Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.9. Philippines Musculoskeletal Disorders Drugs Market
13.7.9.1. Philippines Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.10. Singapore Musculoskeletal Disorders Drugs Market
13.7.10.1. Singapore Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11. South Korea Musculoskeletal Disorders Drugs Market
13.7.11.1. South Korea Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.11.2. South Korea Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.12. Thailand Musculoskeletal Disorders Drugs Market
13.7.12.1. Thailand Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
13.7.13. Vietnam Musculoskeletal Disorders Drugs Market
13.7.13.1. Vietnam Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

14. Western Europe Musculoskeletal Disorders Drugs Market
14.1. Western Europe Musculoskeletal Disorders Drugs Market Overview
14.2. Western Europe, Musculoskeletal Disorders Drugs Market, 2020, by Country, Value ($ Billion)
14.3. Western Europe, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
14.4. Western Europe, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
14.5. Western Europe, Musculoskeletal Disorders Drugs Market Metrics
14.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2015-2025, Western Europe Countries
14.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2020, Western Europe Countries
14.6. Western Europe Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Western Europe Musculoskeletal Disorders Drugs Market: Country Analysis
14.7.1. Austria Musculoskeletal Disorders Drugs Market
14.7.1.1. Austria Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Belgium Musculoskeletal Disorders Drugs Market
14.7.2.1. Belgium Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Denmark Musculoskeletal Disorders Drugs Market
14.7.3.1. Denmark Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. Finland Musculoskeletal Disorders Drugs Market
14.7.4.1. Finland Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. France Musculoskeletal Disorders Drugs Market
14.7.5.1. France Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. France Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Germany Musculoskeletal Disorders Drugs Market
14.7.6.1. Germany Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Germany Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Ireland Musculoskeletal Disorders Drugs Market
14.7.7.1. Ireland Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. Italy Musculoskeletal Disorders Drugs Market
14.7.8.1. Italy Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Netherlands Musculoskeletal Disorders Drugs Market
14.7.9.1. Netherlands Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Norway Musculoskeletal Disorders Drugs Market
14.7.10.1. Norway Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. Portugal Musculoskeletal Disorders Drugs Market
14.7.11.1. Portugal Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Spain Musculoskeletal Disorders Drugs Market
14.7.12.1. Spain Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Sweden Musculoskeletal Disorders Drugs Market
14.7.13.1. Sweden Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.14. Switzerland Musculoskeletal Disorders Drugs Market
14.7.14.1. Switzerland Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15. UK Musculoskeletal Disorders Drugs Market
14.7.15.1. UK Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.15.2. UK Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

15. Eastern Europe Musculoskeletal Disorders Drugs Market
15.1. Eastern Europe Musculoskeletal Disorders Drugs Market Overview
15.2. Eastern Europe, Musculoskeletal Disorders Drugs Market, 2020, by Country, Value ($ Billion)
15.3. Eastern Europe, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
15.4. Eastern Europe, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
15.5. Eastern Europe, Musculoskeletal Disorders Drugs Market Metrics
15.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2015-2025, Eastern Europe Countries
15.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2020, Eastern Europe Countries
15.6. Eastern Europe Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Eastern Europe Musculoskeletal Disorders Drugs Market: Country Analysis
15.7.1. Czech Republic Musculoskeletal Disorders Drugs Market,
15.7.1.1. Czech Republic Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Poland Musculoskeletal Disorders Drugs Market
15.7.2.1. Poland Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Romania Musculoskeletal Disorders Drugs Market
15.7.3.1. Romania Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Russia Musculoskeletal Disorders Drugs Market
15.7.4.1. Russia Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4.2. Russia Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

16. North America Musculoskeletal Disorders Drugs Market
16.1. North America Musculoskeletal Disorders Drugs Market Overview
16.2. North America, Musculoskeletal Disorders Drugs Market, 2020, by Country, Value ($ Billion)
16.3. North America, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
16.4. North America, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
16.5. North America, Musculoskeletal Disorders Drugs Market Metrics
16.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2015-2025, North America Countries
16.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2020, North America Countries
16.6. North America Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. North America Musculoskeletal Disorders Drugs Market: Country Analysis
16.7.1. Canada Musculoskeletal Disorders Drugs Market
16.7.1.1. Canada Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Mexico Musculoskeletal Disorders Drugs Market
16.7.2.1. Mexico Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. USA Musculoskeletal Disorders Drugs Market
16.7.3.1. USA Musculoskeletal Disorders Drugs Market Overview
16.7.3.2. USA Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3.3. USA Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

17. South America Musculoskeletal Disorders Drugs Market
17.1. South America Musculoskeletal Disorders Drugs Market Overview
17.2. South America, Musculoskeletal Disorders Drugs Market, 2020, by Country, Value ($ Billion)
17.3. South America, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
17.4. South America, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
17.5. South America, Musculoskeletal Disorders Drugs Market Metrics
17.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2015-2025, South America Countries
17.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2020, South America Countries
17.6. South America Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. South America Musculoskeletal Disorders Drugs Market: Country Analysis
17.7.1. Argentina Musculoskeletal Disorders Drugs Market
17.7.1.1. Argentina Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Brazil Musculoskeletal Disorders Drugs Market
17.7.1.1. Brazil Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2.2. Brazil Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. Chile Musculoskeletal Disorders Drugs Market
17.7.3.1. Chile Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.4. Colombia Musculoskeletal Disorders Drugs Market
17.7.4.1. Colombia Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.5. Peru Musculoskeletal Disorders Drugs Market
17.7.5.1. Peru Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.6. Venezuela Musculoskeletal Disorders Drugs Market
17.7.6.1. Venezuela Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

18. Middle East Musculoskeletal Disorders Drugs Market
18.1. Middle East Musculoskeletal Disorders Drugs Market Overview
18.2. Middle East, Musculoskeletal Disorders Drugs Market, 2020, by Country, Value ($ Billion)
18.3. Middle East, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
18.4. Middle East, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
18.5. Middle East, Musculoskeletal Disorders Drugs Market Metrics
18.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2015-2025, Middle East Countries
18.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2020, Middle East Countries
18.6. Middle East Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. Middle East Musculoskeletal Disorders Drugs Market: Country Analysis
18.7.1. Saudi Arabia Musculoskeletal Disorders Drugs Market
18.7.1.1. Saudi Arabia Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Israel Musculoskeletal Disorders Drugs Market
18.7.2.1. Israel Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Turkey Musculoskeletal Disorders Drugs Market
18.7.3.1. Turkey Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. UAE Musculoskeletal Disorders Drugs Market
18.7.4.1. UAE Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

19. Africa Musculoskeletal Disorders Drugs Market
19.1. Africa Musculoskeletal Disorders Drugs Market Overview
19.2. Africa, Musculoskeletal Disorders Drugs Market, 2020, by Country, Value ($ Billion)
19.3. Africa, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
19.4. Africa, Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
19.5. Africa, Musculoskeletal Disorders Drugs Market Metrics
19.5.1. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2015-2025, Africa Countries
19.5.2. Rheumatoid Arthritis Prevalence Rate, Musculoskeletal Disorders Drugs Market, Musculoskeletal Disorders Drugs Market/Rheumatoid Arthritis Prevalence Rate, 2020, Africa Countries
19.6. Africa Musculoskeletal Disorders Drugs Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Africa Musculoskeletal Disorders Drugs Market: Country Analysis
19.7.1. Egypt Musculoskeletal Disorders Drugs Market
19.7.1.1. Egypt Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Nigeria Musculoskeletal Disorders Drugs Market
19.7.2.1. Nigeria Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. South Africa Musculoskeletal Disorders Drugs Market
19.7.3.1. South Africa Musculoskeletal Disorders Drugs Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)

20. Musculoskeletal Disorders Drugs Market Competitive Landscape
20.1. Competitive Market Overview
20.2. Market Shares
20.3. Company Profiles
20.3.1. F. Hoffmann-La Roche Ltd
20.3.1.1. Company Overview
20.3.1.2. Products and Services
20.3.1.3. Strategy
20.3.1.4. Financial Performance
20.3.2. GlaxosmithKline Plc
20.3.2.1. Company Overview
20.3.2.2. Products and Services
20.3.2.3. Strategy
20.3.2.4. Financial Performance
20.3.3. Pfizer Inc
20.3.3.1. Company Overview
20.3.3.2. Products and Services
20.3.3.3. Strategy
20.3.3.4. Financial Performance
20.3.4. Abbott Laboratories Inc
20.3.4.1. Company Overview
20.3.4.2. Products and Services
20.3.4.3. Strategy
20.3.4.4. Financial Performance
20.3.5. Daiichi Sankyo Company
20.3.5.1. Company Overview
20.3.5.2. Products and Services
20.3.5.3. Strategy
20.3.5.4. Financial Performance

21. Key Mergers and Acquisitions in the Musculoskeletal Disorders Drugs Market

22. Market Background: Pharmaceutical Drugs Market
22.1. Pharmaceutical Drugs Market Characteristics
22.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
22.3. Global Pharmaceutical Drugs Market, 2020, by Region, Value ($ Billion)
22.4. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
22.5. Global Pharmaceutical Drugs Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)

23. Recommendations
23.1. Global Musculoskeletal Disorders Drugs Market in 2025 - Growth Countries
23.2. Global Musculoskeletal Disorders Drugs Market in 2025 - Growth Segments
23.3. Global Musculoskeletal Disorders Drugs Market in 2025 - Growth Strategies

24. Appendix
24.1. NAICS Definitions of Industry Covered in This Report
24.2. Abbreviations
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher

25. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories Inc
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche Ltd
  • GlaxosmithKline Plc
  • Pfizer Inc
Major companies in the musculoskeletal disorders drugs market include F. Hoffmann-La Roche Ltd; GlaxosmithKline Plc; Pfizer Inc; Abbott Laboratories Inc and Daiichi Sankyo Company.

The global musculoskeletal disorders drugs market is expected to grow from $81.08 billion in 2020 to $85.6 billion in 2021 at a compound annual growth rate (CAGR) of 5.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $100.76 billion in 2025 at a CAGR of 4%.

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The musculoskeletal disorders drugs market is segmented into drugs for rheumatoid arthritis; muscle relaxants; and other musculoskeletal disorders drugs.

North America was the largest region in the global musculoskeletal disorders drugs market, accounting for 53% of the market in 2020. Asia Pacific was the second largest region accounting for 28% of the global musculoskeletal disorders drugs market. Africa was the smallest region in the global musculoskeletal disorders drugs market.

Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders.

Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a report by Ernst and Young in 2018, Fortune 500 companies are spending $7.8 billion to comply with GDPR regulations. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market.

The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the Population Reference Bureau, the share of population over the age of 65 in the global population increased from 8% in 2015 to 9% in 2019. The global population aged 65 years or over was 703 million in 2019. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.
Note: Product cover images may vary from those shown
  • F. Hoffmann-La Roche Ltd
  • GlaxosmithKline Plc
  • Pfizer Inc
  • Abbott Laboratories Inc
  • Daiichi Sankyo Company
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll